Fig. 1.

Effect of rOv-ASP-1 on the primary antibody response after immunization with different doses of influenza vaccine. B6 mice were vaccinated with different doses (0.15, 0.3, 1.5, 3 μg) of TIV with and without 20 μg rOv-ASP-1. Influenza-specific antibodies (IgG, IgG1, and IgG2c) in the plasma at weeks 2 and 3 after immunization were determined by ELISA using TIV as antigen. Limitation of detection (LOD) is 250. The experiments were repeated 2 times (3–4 mice/group each time) with similar results. ^*p < 0.05, comparing TIV vs TIV + rOv-ASP-1 at each dose of vaccine.